PSR claimed that OrphanIQ reduces the time spent by the companies involved in orphan drug development to ask a short question on a variety of topics by avoiding time-consuming agreements and contracts.
PSR said that using the OrphanIQ questions will be handled by the relevant expert, who will first assess whether the question can be answered without obtaining further information, and within a reasonable time-frame, and will subsequently provide a written answer.
Anthony Hall, chief medical officer of PSR, said: “We often come across companies who are thinking of developing their drug according to the Orphan Drug legislation, but are unsure of some of the fundamentals they need to know to get them started.
“OrphanIQ provides such companies an easy and accessible way of gaining insight into this area of drug development.
“Even when the development process is already underway, companies often have short but important questions relating, for example, to their clinical plan or to reimbursement issues.”
Roger Legtenberg, general manager of PSR, said: “The need for this service shows that, even in the non-standard environment that is Orphan Drug Development, practical and quick solutions can be provided for pharmaceutical and biotech companies, without having to put in heavy upfront investments.”